HomeFile

File

View Category
HIGHLIGHTS

CANTOS: Anti-inflammatory Drug Canakinumab Seems to Reduce CV Events

This human monoclonal antibody that specifically targets inflammatory cells seems to reduce cardiovascular events when associated with...
solaci -
Learn More
Acute coronary syndromes

VALIDATE-SWEDEHEART: bivalirudin seems to be losing ground

Another important work that does not see the benefits of bivalirudin over heparin as monotherapy as regards both...
solaci -
Learn More
HIGHLIGHTS

SPYRAL HTN-OFF MED: Renal Denervation Reloaded?

This work presented at the ESC Congress 2017 held in Barcelona, simultaneously published in The Lancet, seems to...
solaci -
Learn More
Antithrombotic Anticoagulants

RE-DUAL PCI: Anti-Thrombotic Management in Patients with Atrial Fibrillation and PCI

RE-DUAL PCI outcomes have been published by the  New England Journal of Medicine along with their presentation at...
solaci -
Learn More
Antiplatelet

Dual antiplatelet therapy discontinuation causes more thrombotic events at 12 months

Several randomized studies have shown that dual antiplatelet therapy (DAPT) is as effective to prevent thrombotic events in...
solaci -
Learn More
Acute coronary syndromes

Early Invasive Strategy Benefits High-Risk Patients

Early angiography is not associated with a reduction in mortality compared with a more delayed invasive strategy...
solaci -
Learn More
Chronic Ischemic cardiopathy

Striking Finding on Diabetes and Bypass Graft Patency

The higher rate of restenosis in the diabetic population is historic and has been reproduced in all studies...
solaci -
Learn More
Structural heart disease

Positive Outcomes of CoreValve Evolut in Large Population

The Evolut R, as well as its predecessor the CoreValve, is a self-expandable valve, supra-annular, made of porcine pericardium...
solaci -
Learn More